i-FACTOR Peptide Enhanced Graft Substitute
Cerapedics, LLC · Decision date Apr 7, 2026
What did the FDA decide?
FDA records P140019/S013 as a supplement to PMA P140019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 7, 2026.
FDA approval order statement
Change in the location for performance of the mass spectral analysis for the P-15 drug substance release specification from SGS North America (NAM), Inc, West Chester PA as a contract laboratory to Bachem Americas to being performed inhouse at Bachem Americas, Torrence, CA
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Apr 7, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140019/S013
- Regulatory pathway
- PMA supplement
- Applicant
- Cerapedics, LLC
- Product code
- NOX
- Decision code
- OK30
- Decision date
- Apr 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Filler, bone void, synthetic peptide.
- Applicant
- Cerapedics, LLC
- Product code
- NOX
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140019 · Original PMA
I-FACTOR PEPTIDE ENHANCED BONE GRAFT
P140019/S013 received
Application receipt date recorded by FDA.
P140019/S013 · FDA decision
30-Day Notice
P140019/S014 · Related supplement
i-F ACTOR Peptide Enhanced Graft Substitute
Timeline entries are records held by MedtechLedger for P140019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cerapedics, LLC | PMA approval | Nov 3, 2015 | FDA | |
i-F ACTOR Peptide Enhanced Graft SubstituteP140019/S014 | Cerapedics, LLC | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code NOX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PearlMatrixTM Peptide Enhanced Bone GraftP240001/S003 | Cerapedics, Inc. | PMA supplement | Sep 16, 2026 | FDA |
PearlMatrix Peptide Enhanced Bone GraftP240001/S002 | Cerapedics, Inc. | PMA supplement | Apr 7, 2026 | FDA |
| Cerapedics, Inc. | PMA supplement | Dec 11, 2025 | FDA | |
PearlMatrix Bone GraftP240001 | Cerapedics, Inc. | PMA approval | Jun 18, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cerapedics, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11025 Dover St., Suite 1600, Westminster, CO, 80021
Sources and methodology
- Original FDA record: P140019/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

